Skip to main content

Susan Gail Kreissman

Professor of Pediatrics
Pediatrics, Hematology-Oncology
Box 102382 DUMC, Durham, NC 27710
393 Hanes House, Durham, NC 27710

Research Interests


Clinical Trials for Pediatric Cancer

Selected Grants


ALTE15N2 STUDY

Clinical TrialPrincipal Investigator · Awarded by Children's Hospital of Philadelphia · 2017 - 2021

COG Work Order AAML: 1031--Millennium Pharmaceuticals, Inc.

Clinical TrialPrincipal Investigator · Awarded by Children's Hospital of Philadelphia · 2013 - 2021

COG WORK ORDER: (PROJECT: EVERYCHILD (APEC14B1) PCR - COG FOUNDATION

Clinical TrialPrincipal Investigator · Awarded by Children's Hospital of Philadelphia · 2015 - 2021

COG WORK ORDER: (PROJECT: PEDIATRIC MATCH (APEC1621SC) PCR - COG FOUNDATION

ResearchPrincipal Investigator · Awarded by Children's Hospital of Philadelphia · 2017 - 2020

COG Work Order: AALL1131: Ph III Clofarabine in High Risk B ALL

Clinical TrialPrincipal Investigator · Awarded by Children's Hospital of Philadelphia · 2015 - 2020

COG WORK ORDER: BIQSFP AALL1131

Clinical TrialPrincipal Investigator · Awarded by Children's Hospital of Philadelphia · 2016 - 2019

A Phase I trial of pomalidomide for children with recurrent, progressive or refractory CNS tumors

Clinical TrialPrincipal Investigator · Awarded by St. Jude Children's Research Hospital · 2015 - 2017

Pediatric Brain Tumor Consortium

Clinical TrialPrincipal Investigator · Awarded by St. Jude Children's Research Hospital · 2014 - 2017

Stroma Biology Identifies Heparin as a Differentiating Agent in Neuroblastoma

ResearchCo Investigator · Awarded by Alex's Lemonade Stand · 2013 - 2015

COG Work Order AALL07P1--Millennium Pharmaceuticals, Inc.

Clinical TrialPrincipal Investigator · Awarded by Children's Hospital of Philadelphia · 2013 - 2015

External Relationships


  • Allterum Therapeutics
  • Champions Oncology
  • Eli Lilly & Co.
  • Johnson & Johnson
  • MMS Holdings
  • US WorldMeds

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.